Piper Sandler Starts Capricor Therapeutics (CAPR) at Overweight

Piper Sandler analyst Edward Tenthoff initiates coverage on Capricor Therapeutics (NASDAQ: CAPR) with a Overweight rating and a price target of $35.00.

The analyst comments: "Capricor is developing deramiocel (CAP-1002) to treat cardiomyopathy in Duchenne Muscular Dystrophy (DMD) boys. In the Phase II HOPE-2 trial (N=20), deramiocel slowed LVEF decline by 107% vs. placebo at 12 months. (p=0.002) At World Muscle Society, HOPE-2 OLE data showed deramiocel achieved an 8.1 point improvement in median LVEF and 11.0ml/m2 benefit in median End Systolic Volume vs. external controls at 2 years with benefit maintained out to 3 years. Capricor has begun the rolling BLA submission, and deramiocel could gain FDA approval for DMD cardiomyopathy in 2H:25. Deramiocel is partnered globally with Nippon Shinyaku with Capricor retaining 30-50% of potential blockbuster revenues, plus up to $1.5 billion in milestones. Capricor recently issued 5.1 million shares at $17 raising gross proceeds of $86 million, bringing pro forma cash to ~ $198 million excluding 3Q:24 burn."

For an analyst ratings summary and ratings history on Capricor Therapeutics click here. For more ratings news on Capricor Therapeutics click here.

Shares of Capricor Therapeutics closed at $18.86 yesterday.

You May Also Be Interested In

• Citi Downgrades Legal & General Group PLC (LGEN:LN) (LGGNF) to Sell
• Ashland said to explore sale amid takeover interest - Bloomberg
• JPMorgan Starts Shanghai V-Test Semiconductor (688372:CH) at Overweight